Cost-effectiveness of Roux-en-Y gastric bypass in type 2 diabetes patients.

Sep 15, 2009The American journal of managed care

Cost-effectiveness of Roux-en-Y gastric bypass surgery in people with type 2 diabetes

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗

Abstract

The incremental cost-effectiveness ratio (ICER) for Roux-en-Y gastric bypass in treating type 2 diabetes mellitus is $21,973 per quality-adjusted life-year (QALY) gained.

Roux-en-Y gastric bypass may be a cost-effective treatment for type 2 diabetes compared to standard medical management.
The analysis used a predictive health economic model based on clinical data from a prospective observational study.
Shortening the time horizon to 5 or 10 years significantly increased the cost per QALY gained.
Excluding the negative impact of increased body mass index on quality of life also adversely affected the cost-effectiveness.
Overall, the procedure remains cost-effective when considering longer time frames and the full quality-of-life implications.

AI simplified

OBJECTIVE: To assess the cost-effectiveness of Roux-en-Y gastric bypass for treating type 2 diabetes mellitus (T2DM) in the United States compared with standard medical management, using clinical data from a prospective observational study conducted at an academic medical center.

STUDY DESIGN: Our study used a predictive health economic model (the CORE Diabetes Model) to project the long-term costs and clinical effectiveness of Roux-en-Y gastric bypass as a treatment for T2DM using the prospective observational study as the basis for our clinical effectiveness assumptions.

METHODS: The CORE Diabetes Model used Monte Carlo simulation with tracker variables to estimate the lifetime costs and clinical outcomes of Roux-en-Y gastric bypass compared with standard medical management of obese T2DM patients. Sensitivity analyses were performed on key clinical assumptions, discount rates, and shorter time horizons.

RESULTS: The base-case scenario yielded an incremental cost-effectiveness ratio (ICER) of $21,973 per quality-adjusted life-year (QALY) gained. In sensitivity analyses, shortening the time horizon to 5 and 10 years and excluding the negative impact of increased body mass index on the patient's quality of life had the greatest adverse impact on the ICERs (ie, higher cost per QALY).

CONCLUSIONS: Under base-case assumptions, Roux-en-Y gastric bypass is cost-effective in the treatment of T2DM in the United States with an ICER below $50,000 per QALY gained. Sensitivity analyses indicated that bariatric surgery is not cost-effective over shorter time horizons, or if the negative quality-of-life impact of increased body mass index is ignored.

Cost-effectiveness of Roux-en-Y gastric bypass in type 2 diabetes patients.

Abstract

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief